Very early researchStudy completedNCT05725070What this trial is testingPhase 0/1 Study of 212Pb-NG001 in mCRPCWho this might be right forMetastatic Castration-resistant Prostate Cancer ARTBIO Inc. 3
Testing effectiveness (Phase 2)UnknownNCT05262608What this trial is testingThe Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationWho this might be right forProstate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 30
Post-approval studies (Phase 4)Study completedNCT02485691What this trial is testingCabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentWho this might be right forProstate Cancer Metastatic Sanofi 255
Testing effectiveness (Phase 2)Looking for participantsNCT06267729What this trial is testingStudy of AZD0754 in Participants With Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer AstraZeneca 60
Early research (Phase 1)Not Yet RecruitingNCT06866795What this trial is testingPhase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)Who this might be right forMetastatic Castration Resistant Prostate Cancer Geode Therapeutics Inc. 42
Testing effectiveness (Phase 2)Looking for participantsNCT06236139What this trial is testingCell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8 Fred Hutchinson Cancer Center 48
Early research (Phase 1)Ended earlyNCT04629781What this trial is testingOpen-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPCWho this might be right forMetastatic Castration-resistant Prostate Cancer Swiss Cancer Institute 11
Not applicableWithdrawnNCT02130947What this trial is testingExercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or EnzalutamideWho this might be right forMetastatic Castration Resistant Prostate Cancer (mCRPC) UNC Lineberger Comprehensive Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06401980What this trial is testingDarolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Who this might be right forMetastatic Castration-resistant Prostate Cancer Swiss Cancer Institute 162
Large-scale testing (Phase 3)Active Not RecruitingNCT04647526What this trial is testingStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentWho this might be right forMetastatic Castration-Resistant Prostate Cancer POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 455
Not applicableNot Yet RecruitingNCT07697989What this trial is testingPluvicto Real-world Investigation in Survival in Metastatic CRPCWho this might be right forProstatic Neoplasms, Castration-ResistantNeoplasm Metastasis Novartis Pharmaceuticals 1,085
Very early researchLooking for participantsNCT07798778What this trial is testingClinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostate Cancer Affiliated Hospital of Jiangnan University 18
Testing effectiveness (Phase 2)UnknownNCT02266745What this trial is testingA Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsWho this might be right forAdvanced Solid TumorsCRPCmCRPC+6 more Promontory Therapeutics Inc. 109
Testing effectiveness (Phase 2)Ended earlyNCT04918810What this trial is testingBiomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate CancerWho this might be right forCastration Resistant Prostatic Cancer Australian and New Zealand Urogenital and Prostate Cancer Trials Group 6
Testing effectiveness (Phase 2)Study completedNCT01818986What this trial is testingSipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)Who this might be right forMetastatic Castrate-resistant Prostate CancermCRPC University of Texas Southwestern Medical Center 20
Early research (Phase 1)Looking for participantsNCT04221542What this trial is testingStudy of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer Amgen 479
Early research (Phase 1)Temporarily pausedNCT05425862What this trial is testingPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerWho this might be right forMetastatic Castration Resistant Prostate Cancer (mCRPC) Peter MacCallum Cancer Centre, Australia 48
Testing effectiveness (Phase 2)Study completedNCT04862091What this trial is testingComparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Jiangsu HengRui Medicine Co., Ltd. 69
Early research (Phase 1)Looking for participantsNCT05107674What this trial is testingNX-1607 in Adults With Advanced MalignanciesWho this might be right forOvarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more Nurix Therapeutics, Inc. 345
Early research (Phase 1)Looking for participantsNCT07533708What this trial is testingA Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced TumoursWho this might be right formCRPC or Advanced/Metastatic Solid Tumors Shanghai Henlius Biotech 48